{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:55:01Z","timestamp":1794855301597,"version":"4.9.1"},"reference-count":23,"publisher":"Index Copernicus","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2024,8,19]]},"abstract":"<jats:p>&lt;b&gt;Introduction:&lt;\/b&gt; Despite clear, relatively easy-to-use guidance, many clinicians find the perioperative management of direct oral anticoagulants (DOACs) challenging. Inappropriate antithrombotic management can delay procedures and lead to bleeding or thromboembolic complications.&lt;b&gt;Aim:&lt;\/b&gt; We aimed to describe perioperative management practices related to planned procedures regarding DOACs in accordance with the applicable guidelines of cardiological and surgical societies.&lt;b&gt;Results:&lt;\/b&gt; Perioperative management of DOAC therapy depends on many factors, and recommendations in the guidelines are not consistent.&lt;b&gt;Conclusions:&lt;\/b&gt; The best approach to managing these patients is therefore to strike a balance between the risks of bleeding and thromboembolism.<\/jats:p>","DOI":"10.5604\/01.3001.0054.7091","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:08:02Z","timestamp":1727183282000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative Elective Management in Patients Treated with Direct Oral Anticoagulants \u2013 Practical Guide"],"prefix":"10.5604","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7619-8426","authenticated-orcid":false,"given":"Iwona","family":"Gorczyca-G\u0142owacka","sequence":"first","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"W\u00f3jcik","sequence":"additional","affiliation":[{"name":"Surgery Department, Multi-specialty Hospital, Ostrowiec Swietokrzyski, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Nawacki","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tomaszuk-Kazberuk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lipidology and Internal Medicine with Intensive Cardiac Care Unit, Medical University, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"G\u0142uszek","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","reference":[{"key":"623603r1","doi-asserted-by":"crossref","unstructured":"Hindricks G., Potpara T., Dagres N. et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration withthe European Association for Cardio-Thoracic Surgery (EACTS): The TaskForce for the diagnosis and management of atrial fibrillation of the EuropeanSociety of Cardiology (ESC) Developed with the special contribution of theEuropean Heart Rhythm Association (EHRA) of the ESC. Eur Heart J., 2021;42(5): 373\u2013498. doi: 10.1093\/eurheartj\/ehaa612.","DOI":"10.1093\/eurheartj\/ehaa945"},{"key":"623603r2","doi-asserted-by":"crossref","unstructured":"Janion-Sadowska A., Turek \u0141., Dudek A., Andrychowski J., Sadowski M.: Atrialfibrillation and flutter - the state of the art. Part 2. Medical Studies., 2021; 37(3):239\u2013249. doi: 10.5114\/ms.2021.109530.","DOI":"10.5114\/ms.2021.109530"},{"key":"623603r3","doi-asserted-by":"crossref","unstructured":"Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: Dabigatran versus warfarin inpatients with atrial fibrillation. N Engl J Med., 2009; 361(12): 1139\u20131151. doi:10.1056\/NEJMoa0905561.","DOI":"10.1056\/NEJMoa0905561"},{"key":"623603r4","doi-asserted-by":"crossref","unstructured":"Patel M.R., Mahaffey K.W., Garg J. et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med., 2011; 365(10): 883\u2013891. doi: 10.1056\/NEJMoa1009638.","DOI":"10.1056\/NEJMoa1009638"},{"key":"623603r5","doi-asserted-by":"crossref","unstructured":"Granger C.B., Alexander J.H., McMurray J.J. et al.: Apixaban versus warfarinin patients with atrial fibrillation. N Engl J Med., 2011; 365(11): 981\u2013992. doi:10.1056\/NEJMoa1107039.","DOI":"10.1056\/NEJMoa1107039"},{"key":"623603r6","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J., Gelbricht V., F\u00f6rster K. et al.: Peri-interventional management of novel oral anticoagulants in daily care: results from the prospectiveDresden NOAC registry. Eur Heart J., 2014; 35(28): 1888\u20131896. doi: 10.1093\/eurheartj\/eht557.","DOI":"10.1093\/eurheartj\/eht557"},{"key":"623603r7","doi-asserted-by":"crossref","unstructured":"Douketis J.D., Spyropoulos A.C., Murad M.H. et al.: Perioperative Management of Antithrombotic Therapy: An American College of Chest PhysiciansClinical Practice Guideline. Chest., 2022; 162(5): e207\u2013e243. doi: 10.1016\/j.chest.2022.07.025.","DOI":"10.1016\/j.chest.2022.07.025"},{"key":"623603r8","doi-asserted-by":"crossref","unstructured":"Abraham N.S., Barkun A.N., Sauer B.G. et al.: American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. J Can Assoc Gastroenterol.,2022; 5(2): 100\u2013101. doi: 10.1093\/jcag\/gwac010.","DOI":"10.1093\/jcag\/gwac010"},{"key":"623603r9","doi-asserted-by":"crossref","unstructured":"Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J.: Refining clinical riskstratification for predicting stroke and thromboembolism in atrial fibrillationusing a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest., 2010; 137(2): 263\u2013272. doi: 10.1378\/chest.09-1584.","DOI":"10.1378\/chest.09-1584"},{"key":"623603r10","doi-asserted-by":"crossref","unstructured":"Steffel J., Collins R., Antz M. et al.: 2021 European Heart Rhythm AssociationPractical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulantsin Patients with Atrial Fibrillation. Europace., 2021; 23(10): 1612\u20131676. doi:10.1093\/europace\/euab065.","DOI":"10.1093\/europace\/euab157"},{"key":"623603r11","doi-asserted-by":"crossref","unstructured":"Douketis J.D., Spyropoulos A.C., Spencer F.A. et al.: Perioperative management ofantithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical PracticeGuidelines. Chest., 2012; 141(2 Suppl): e326S\u2013e350S. doi: 10.1378\/chest.11-2298.","DOI":"10.1378\/chest.141.4.1129b"},{"key":"623603r12","doi-asserted-by":"crossref","unstructured":"Halvorsen S., Mehilli J., Cassese S. et al.: 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J., 2022; 43(39): 3826\u20133924. doi: 10.1093\/eurheartj\/ehac270.","DOI":"10.1093\/eurheartj\/ehac270"},{"key":"623603r13","doi-asserted-by":"crossref","unstructured":"Douketis J.D., Spyropoulos A.C., Duncan J. et al.: Perioperative Management ofPatients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMAIntern Med., 2019; 179(11): 1469\u20131478. doi: 10.1001\/jamainternmed.2019.2431.","DOI":"10.1001\/jamainternmed.2019.2431"},{"key":"623603r14","doi-asserted-by":"crossref","unstructured":"Shah S., Nayfeh T., Hasan B. et al.: Perioperative Management of Vitamin KAntagonists and Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Chest., 2023; 163(5): 1245\u20131257. doi: 10.1016\/j.chest.2022.11.032.","DOI":"10.1016\/j.chest.2022.11.032"},{"key":"623603r15","doi-asserted-by":"crossref","unstructured":"Godier A., Dincq A.S., Martin A.C. et al.: Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. EurHeart J., 2017; 38(31): 2431\u20132439. doi: 10.1093\/eurheartj\/ehx403.","DOI":"10.1093\/eurheartj\/ehx403"},{"key":"623603r16","doi-asserted-by":"crossref","unstructured":"Shaw J., de Wit C., Le Gal G., Carrier M.: Thrombotic and bleeding outcomesfollowing perioperative interruption of direct oral anticoagulants in patientswith venous thromboembolic disease. J Thromb Haemost., 2017; 15(5): 925\u2013930.doi: 10.1111\/jth.13670.","DOI":"10.1111\/jth.13670"},{"key":"623603r17","doi-asserted-by":"crossref","unstructured":"Shaw J.R., Douketis J., Le Gal G., Carrier M.: Periprocedural interruption ofanticoagulation in patients with cancer-associated venous thromboembolism:an analysis of thrombotic and bleeding outcomes. J Thromb Haemost., 2019;17(7): 1171\u20131178. doi: 10.1111\/jth.14468.","DOI":"10.1111\/jth.14468"},{"key":"623603r18","doi-asserted-by":"crossref","unstructured":"Douxfils J., Chatelain C., Chatelain B., Dogn\u00e9 J.M., Mullier F.: Impact ofapixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost., 2013; 110(2): 283\u2013294. doi: 10.1160\/TH12-12-0898.","DOI":"10.1160\/TH12-12-0898"},{"key":"623603r19","doi-asserted-by":"crossref","unstructured":"Gosselin R.C., Adcock D.M., Bates S.M. et al.: International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost., 2018; 118(3): 437\u2013450.doi: 10.1055\/s-0038-1627480.","DOI":"10.1055\/s-0038-1627480"},{"key":"623603r20","doi-asserted-by":"crossref","unstructured":"Altman R., Gonzalez C.D.: Simple and rapid assay for effect of the new oralanticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J., 2014; 12(1): 7. doi: 10.1186\/1477-9560-12-7.","DOI":"10.1186\/1477-9560-12-7"},{"key":"623603r21","doi-asserted-by":"crossref","unstructured":"Cuker A., Siegal D.M., Crowther M.A., Garcia D.A.: Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.J Am Coll Cardiol., 2014; 64(11): 1128\u20131139. doi: 10.1016\/j.jacc.2014.05.065.","DOI":"10.1016\/j.jacc.2014.05.065"},{"key":"623603r22","doi-asserted-by":"crossref","unstructured":"Writing Committee Members; Joglar J.A., Chung M.K., Armbruster A.L. et al.: 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management ofAtrial Fibrillation: A Report of the American College of Cardiology\/AmericanHeart Association Joint Committee on Clinical Practice Guidelines. J Am CollCardiol., 2024; 83(1): 109\u2013279. doi: 10.1016\/j.jacc.2023.08.017.","DOI":"10.1016\/j.jacc.2023.08.017"},{"key":"623603r23","doi-asserted-by":"crossref","unstructured":"Fanikos J., Murwin D., Gruenenfelder F. et al.: Global use of idarucizumab inclinical practice: outcomes of the RE-VECTO Surveillance Program. ThrombHaemost., 2020; 120(1): 27\u201335. doi: 10.1055\/s-0039-1695771.","DOI":"10.1055\/s-0039-1695771"}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0054.7091","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0054.7091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:56:02Z","timestamp":1730112962000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0054.7091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0054.7091","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"value":"0032-373X","type":"print"},{"value":"2299-2847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}